ClinicalTrials.gg
CompletedNCT02617667Updated Nov 6, 2019Results posted

CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)

A Phase 2 interventional study of Cyclosporine A and Placebo in Dry Eye Syndromes, sponsored by Novaliq GmbH. Completed at 4 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-11-06.

Sponsored by Novaliq GmbH · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
207
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies testing cyclosporine in Dry Eye Syndromes — 5 open to participants now, 5 under way, none of them phase 3. Cyclosporine · Dry Eye Syndromes.

Enrollment
3rd of 41
207 · median 51
Started
2016
with 1 other
Phase 2
4 of 45
none open now
Registered
19th of 45
by date
Lead sponsor
2 of 45
Novaliq GmbH

Among the 45 studies testing cyclosporine in Dry Eye Syndromes, this one is the 3rd largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 19th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

5 of the 45 studies testing cyclosporine in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About cyclosporine

Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing cyclosporine in Dry Eye Syndromes, or all of them as a file.
02

Study summary

The objective of this study was to compare the safety, efficacy, and tolerability of two different dose levels of CyclASol Ophthalmic Solutions to placebo (vehicle) and Restasis for the treatment of the signs and symptoms of Dry Eye Disease (DED).

Read the detailed description

This phase 2 study explored the safety, efficacy and tolerability of two CyclASol concentrations as one drop twice daily versus vehicle (placebo). In addition to the masked vehicle control arm, an open-label comparator arm consisting of Restasis was included.

The study explored a range of signs and symptoms of DED to gain an understanding of the possible treatment effects in comparison to vehicle and estimation of effect sizes. In line with current treatment guidelines, the proposed phase 2 population consisted of patients suffering from moderate to severe DED.

The primary treatment comparisons in this study were between the two CyclASol concentrations versus vehicle for the sign variable total corneal fluorescein staining and the symptom variable dryness severity visual analogue scale at day 113. All other comparisons between treatments groups were considered secondary analyses.

03

Conditions studied

  • Dry Eye Syndromes

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed Form and HIPAA (Health Insurance Portability and Accountability Act ) document
  • Patient-reported history of dry eye in both eyes
  • Current use of over-the-counter and/or prescription eye drops for dry eye symptoms
  • Ability and willingness to follow instructions, including participation in all study assessments and visits

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, nursing or planning a pregnancy
  • Unwillingness to submit a blood pregnancy test at screening and at the last visit (or early termination visit) if of , or unwillingness to use acceptable means of
  • slit-lamp findings or abnormal lid anatomy at screening
  • DED secondary to scarring or ocular or periocular
  • History of herpetic keratitis
  • Active ocular allergies or ocular allergies that are expected to be active during the study period
  • Ongoing ocular or systemic infection at screening or baseline
  • Wear of contact lenses within 3 months prior to screening or anticipated use of contact lenses during the study
  • History of no response to previous topical Cyclosporine A and/or use of topical Cyclosporine A within 6 months prior to screening
  • Intra-ocular surgery or ocular laser surgery within the previous 6 months, or have any planned ocular and/or lid surgeries over the study period
  • Presence of an uncontrolled systemic disease
  • Presence of a known allergy and/or sensitivity to the study drug or its components
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    CyclASol Ophthalmic Solution 1

    Cyclosporine A solution (dose-level 1) in vehicle

    Drug: Cyclosporine A

  • Experimental
    CyclASol Ophthalmic Solution 2

    Cyclosporine A solution (dose-level 2) in vehicle

    Drug: Cyclosporine A

  • Placebo comparator
    Placebo Ophthalmic Solution

    Vehicle only

    Drug: Placebo

  • Active comparator
    Restasis

    Cyclosporine A 0.05% ophthalmic emulsion

    Drug: Cyclosporine A

Interventions

  • topical ocular, eye drops

    Also known as: Ciclosporin, CsA

  • DrugPlacebo

    topical ocular, eye drops

    Also known as: Excipient

06

What researchers measure

Primary outcomes

  1. Change From Baseline (Visit 1) in Total Corneal Fluorescein Staining at 113 Days

    The primary analysis and objective of the study was to compare the two CyclASol groups versus vehicle (all blinded treatment arms) for one sign and one symptom endpoint. The open label active comparator arm was not included in the primary analysis to reduce the number of comparisons. The sign endpoint was the change from baseline in total corneal fluorescein staining at day 113. The cornea is divided into five regions: central, superior, inferior, nasal and temporal. Each region is graded from 0-3 based on the National Eye Institute scale, where 0 indicates no staining and 3 maximal staining. The total score is the sum of all these regions. The maximum score for each eye is 15.

    Time frame: Baseline to 113 Days

  2. Change From Baseline (Visit 1) in Dryness Severity Visual Analog Scale (VAS) at 113 Days

    The primary analysis and objective of the study was to compare the the two CyclASol groups versus vehicle (all blinded treatment arms) for one sign and one symptom endpoint. The open label active comparator arm was not included in the primary analysis to reduce the number of comparisons. Furthermore, the open label character could have had an impact on patient reported outcomes. The symptom endpoint was the change from baseline in severity of dryness VAS at Day 113. Dryness severity was rated from 0 to 100%, where 0% corresponds to "no dryness" and 100% corresponds to "maximum dryness".

    Time frame: Baseline to 113 Days

07

Results

Posted Jul 26, 2018

Participant flow

Participant flow — Overall Study
MilestoneCyclASol 0.05% Ophthalmic SolutionCyclASol 0.1% Ophthalmic SolutionPlacebo Ophthalmic SolutionRestasis
Started51515253
Completed50504852
Not completed1141

Outcome measures

PrimaryChange From Baseline (Visit 1) in Total Corneal Fluorescein Staining at 113 Days

The primary analysis and objective of the study was to compare the two CyclASol groups versus vehicle (all blinded treatment arms) for one sign and one symptom endpoint. The open label active comparator arm was not included in the primary analysis to reduce the number of comparisons. The sign endpoint was the change from baseline in total corneal fluorescein staining at day 113. The cornea is divided into five regions: central, superior, inferior, nasal and temporal. Each region is graded from 0-3 based on the National Eye Institute scale, where 0 indicates no staining and 3 maximal staining. The total score is the sum of all these regions. The maximum score for each eye is 15.

Time frame:
Baseline to 113 Days
Reported as:
Mean · units on a scale
Change From Baseline (Visit 1) in Total Corneal Fluorescein Staining at 113 Days
units on a scaleCyclASol 0.05% Ophthalmic SolutionCyclASol 0.1% Ophthalmic SolutionPlacebo Ophthalmic Solution
Change From Baseline (Visit 1) in Total Corneal Fluorescein Staining at 113 Days-2.38 ± 2.156-2.10 ± 2.252-1.69 ± 2.619
PrimaryChange From Baseline (Visit 1) in Dryness Severity Visual Analog Scale (VAS) at 113 Days

The primary analysis and objective of the study was to compare the the two CyclASol groups versus vehicle (all blinded treatment arms) for one sign and one symptom endpoint. The open label active comparator arm was not included in the primary analysis to reduce the number of comparisons. Furthermore, the open label character could have had an impact on patient reported outcomes. The symptom endpoint was the change from baseline in severity of dryness VAS at Day 113. Dryness severity was rated from 0 to 100%, where 0% corresponds to "no dryness" and 100% corresponds to "maximum dryness".

Time frame:
Baseline to 113 Days
Reported as:
Mean · units on a scale
Change From Baseline (Visit 1) in Dryness Severity Visual Analog Scale (VAS) at 113 Days
units on a scaleCyclASol 0.05% Ophthalmic SolutionCyclASol 0.1% Ophthalmic SolutionPlacebo Ophthalmic Solution
Change From Baseline (Visit 1) in Dryness Severity Visual Analog Scale (VAS) at 113 Days-11.00 ± 19.362-9.30 ± 27.832-13.85 ± 25.301

Adverse events

Collected over Adverse events reported were documented from the first dose of randomized study drug until the end of the last study day visit (day 113). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CyclASol 0.05% Ophthalmic Solution0/51 (0%)2/51 (3.9%)5/51 (9.8%)
CyclASol 0.1% Ophthalmic Solution0/51 (0%)0/51 (0%)4/51 (7.8%)
Placebo Ophthalmic Solution0/52 (0%)0/52 (0%)4/52 (7.7%)
Restasis0/53 (0%)1/53 (1.9%)4/53 (7.5%)
Most frequent serious events
Most frequent serious events
EventCyclASol 0.05% Ophthalmic SolutionCyclASol 0.1% Ophthalmic SolutionPlacebo Ophthalmic SolutionRestasis
Acute coronary syndromeCardiac disorders1/510/510/520/53
Myocardial infarctionCardiac disorders1/510/510/520/53
Ovarian CystReproductive system and breast disorders0/510/510/521/53
Most frequent other events
Most frequent other events
EventCyclASol 0.05% Ophthalmic SolutionCyclASol 0.1% Ophthalmic SolutionPlacebo Ophthalmic SolutionRestasis
Visual acuity reducedEye disorders2/514/511/524/53
NasopharyngitisInfections and infestations3/510/513/520/53

Baseline characteristics

The full analysis set included all randomized participants.

Age, Continuous
Age, Continuous(years)CyclASol 0.05% Ophthalmic SolutionCyclASol 0.1% Ophthalmic SolutionPlacebo Ophthalmic SolutionRestasisTotal
Mean64.3 ± 10.7261.1 ± 12.2961.3 ± 10.4562.8 ± 11.2062.4 ± 11.36
Sex: Female, Male
Sex: Female, Male(Participants)CyclASol 0.05% Ophthalmic SolutionCyclASol 0.1% Ophthalmic SolutionPlacebo Ophthalmic SolutionRestasisTotal
Female38363940153
Male1315131354
08

Study locations

4 sites
  • CYS-002 Investigational Site
    Newport Beach, California 92663, United States
  • CYS-002 Investigational Site
    Lewiston, Maine 04240, United States
  • CYS-002 Investigational Site
    Andover, Massachusetts 01810, United States
  • CYS-002 Investigational Site
    Quincy, Massachusetts 02169, United States
09

References and documents

Publications

  • Wirta DL, Torkildsen GL, Moreira HR, Lonsdale JD, Ciolino JB, Jentsch G, Beckert M, Ousler GW, Steven P, Krosser S. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease. Ophthalmology. 2019 Jun;126(6):792-800. doi: 10.1016/j.ophtha.2019.01.024. Epub 2019 Jan 28. PubMed 30703441 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2016, a primary completion of Jul 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2018, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2015
First posted
Dec 1, 2015
Start
Jan 2016
Primary completionActual
Jul 2016
CompletionActual
Sep 2016
Results first posted
Jul 26, 2018
Last update
Nov 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02617667
Lead sponsor
Novaliq GmbH
Responsible party
Sponsor
First posted
Dec 1, 2015
Start date
Jan 2016
Primary completion
Jul 2016
Completion
Sep 2016
Results posted
Jul 26, 2018
Last update
Nov 6, 2019

Study contacts

Sonja Kroesser, Dr.sc.hum.
study director · Novaliq GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion